HOME >> MEDICINE >> NEWS
First mouse model for multiple system atrophy points to new treatment targets for brain diseases

(Philadelphia, PA) A newly developed animal model for Multiple System Atrophy (MSA) a collection of neurodegenerative disorders once thought to be three separate diseases sheds new light on this little-studied brain disease, according to research from investigators at the University of Pennsylvania School of Medicine.

Virginia M.-Y. Lee, PhD, Director of Penn's Center for Neurodegenerative Disease Research, and colleagues demonstrated that the mice showed symptoms similar to human MSA. These include an accumulation of a protein called -synuclein in oligodendrocytes cells that produce the protective myelin sheath that covers axons. This protein accumulation disables oligodendrocytes, leading to a loss of the sheath on neurons and eventually nerve-cell malfunction and death. The mice also showed slowly progressive problems with their motor skills associated with the nerve-cell damage. Neurons are important in transmitting signals and in maintaining learning and memory.

"The uniqueness of this disease is that, unlike most of the neurodegenerative diseases, which affect neurons primarily and oligodendrocytes secondarily, this is the other way around," says Lee. In fact, there is growing evidence that non-neuronal cells also play a role in amyloid deposits in Alzheimer's disease and amyotrophic lateral sclerosis (ALS) mouse models. Lee and colleagues report their findings in the March 24, 2005 issue of Neuron.

MSA is so named because it affects multiple parts of the nervous system. Initially MSA was given three names, based on the symptoms physicians had observed. However, when they closely examined patients' pathology, the disorders seemed related, based on the -synuclein proteins in cells. In the clinic, many patients with MSA present with symptoms similar to Parkinson's disease (PD), and MSA has been misdiagnosed as such.

Collectively, MSA now includes three related disorders characterized by their most prominent symptoms: olivopo
'"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-662-2560
University of Pennsylvania School of Medicine
23-Mar-2005


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
4. First US kidney cancer vaccine trial underway at Columbia
5. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
6. First blood test to diagnose paralyzing, blinding disease
7. First US SARS vaccine trial opens at NIH
8. First-ever safety study of medical cannabis use in Canada launched
9. First solid evidence that the study of music promotes intellectual development
10. First medical test on CD gets good results
11. First proof that cutting Rx drugs due to cost harms health

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... 22, 2017 AVACEN Medical (AVACEN) announced that ... successfully helping those with the widespread pain associated with ... Amanda in Essex, England commented, ... hair, experiencing no sleep at all, tremendous pain, with ... cannot recommend [the AVACEN 100] enough, how this has ...
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
Breaking Medicine Technology:
Cached News: